165 related articles for article (PubMed ID: 8443749)
1. Serum tumor markers CEA, CA 50, TATI, and NSE in lung cancer screening.
Järvisalo J; Hakama M; Knekt P; Stenman UH; Leino A; Teppo L; Maatela J; Aromaa A
Cancer; 1993 Mar; 71(6):1982-8. PubMed ID: 8443749
[TBL] [Abstract][Full Text] [Related]
2. Tumour-associated trypsin inhibitor (TATI) in patients with colorectal cancer: a comparison with CEA, CA 50 and CA 242.
Pasanen P; Eskelinen M; Kulju A; Penttilä I; Janatuinen E; Alhava E
Scand J Clin Lab Invest; 1995 Apr; 55(2):119-24. PubMed ID: 7667604
[TBL] [Abstract][Full Text] [Related]
3. Tumor-associated trypsin inhibitor (TATI) in benign and malignant gastric disease.
Loizate Toricaguena A; Lamiquiz Vallejo A; Dominguez Merru-Urrutia MJ; Legorburu Escudero JF
Scand J Clin Lab Invest Suppl; 1991; 207():59-62. PubMed ID: 1780694
[TBL] [Abstract][Full Text] [Related]
4. Clinical usefulness of serum assays of neuron-specific enolase, carcinoembryonic antigen and CA-50 antigen in the diagnosis of lung cancer.
Bergman B; Brezicka FT; Engström CP; Larsson S
Eur J Cancer; 1993; 29A(2):198-202. PubMed ID: 8380696
[TBL] [Abstract][Full Text] [Related]
5. Tumor-associated trypsin inhibitor (TATI) in patients with colorectal carcinoma. A critical comparison with CEA.
Catarino M; Conde R
Scand J Clin Lab Invest Suppl; 1991; 207():43-6. PubMed ID: 1780689
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated trypsin inhibitor, TATI, in gastrointestinal cancer and related benign diseases.
Piantino P; Arosaio E
Scand J Clin Lab Invest Suppl; 1991; 207():67-9. PubMed ID: 1780697
[TBL] [Abstract][Full Text] [Related]
7. Serum NSE, CEA, CT, CA 15-3 levels in human lung cancer.
Nutini S; Cappelli G; Benucci A; Catalani C; Nozzoli F
Int J Biol Markers; 1990; 5(4):198-202. PubMed ID: 1965544
[TBL] [Abstract][Full Text] [Related]
8. Tumour markers and screening for gastrointestinal cancer: a follow up study in Finland.
Hakama M; Stenman UH; Knekt P; Järvisalo J; Leino A; Hakulinen T; Maatela J; Aromaa A
J Med Screen; 1994 Jan; 1(1):60-4. PubMed ID: 8790487
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
Masson P; Pålsson B; Andren-Sandberg A
Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
[TBL] [Abstract][Full Text] [Related]
10. Clinical utility of haptoglobin in combination with CEA, NSE and CYFRA21-1 for diagnosis of lung cancer.
Wang B; He YJ; Tian YX; Yang RN; Zhu YR; Qiu H
Asian Pac J Cancer Prev; 2014; 15(22):9611-4. PubMed ID: 25520076
[TBL] [Abstract][Full Text] [Related]
11. Identifying the Best Marker Combination in CEA, CA125, CY211, NSE, and SCC for Lung Cancer Screening by Combining ROC Curve and Logistic Regression Analyses: Is It Feasible?
Yang Q; Zhang P; Wu R; Lu K; Zhou H
Dis Markers; 2018; 2018():2082840. PubMed ID: 30364165
[TBL] [Abstract][Full Text] [Related]
12. Tumor-associated trypsin inhibitor in pancreatic diseases.
Aroasio E; Piantino P
Scand J Clin Lab Invest Suppl; 1991; 207():71-3. PubMed ID: 1723534
[TBL] [Abstract][Full Text] [Related]
13. Tumor-associated trypsin inhibitor (TATI) in the diagnosis of lung cancer.
Pecchio F; Rapellino M; Baldi S; Casali V; Libertucci D; Coni F
Scand J Clin Lab Invest Suppl; 1991; 207():63-4. PubMed ID: 1780695
[TBL] [Abstract][Full Text] [Related]
14. Serum levels of CA-50, CA-19.9, CA-125, neuron specific enolase and carcinoembryonic antigen in lung cancer and benign diseases of the lung.
Berthiot G; Marechal F; Cattan A; Deltour G
Biomed Pharmacother; 1989; 43(8):613-20. PubMed ID: 2631977
[TBL] [Abstract][Full Text] [Related]
15. Cancer-associated antigen CA 195 in patients with mucinous ovarian tumours: a comparative analysis with CEA, TATI and CA 125 in serum specimens and cyst fluids.
de Bruijn HW; ten Hoor KA; Boonstra H; Marrink J; Krans M; Aalders JG
Tumour Biol; 1993; 14(2):105-15. PubMed ID: 8392219
[TBL] [Abstract][Full Text] [Related]
16. Determination of the best prognostic value of serum tumor markers in patients with suspected lung cancer in an Iranian population.
Sigari N; Mohsenpour B; Nikkhoo B; Ghaderi B; Afkhamzadeh A; Azadi NA; Fathi F; Abdi M
Clin Lab; 2014; 60(1):23-7. PubMed ID: 24600971
[TBL] [Abstract][Full Text] [Related]
17. Thymidine kinase 1 combined with CEA, CYFRA21-1 and NSE improved its diagnostic value for lung cancer.
Jiang ZF; Wang M; Xu JL
Life Sci; 2018 Feb; 194():1-6. PubMed ID: 29247745
[TBL] [Abstract][Full Text] [Related]
18. Increased lung cancer risk in patients with interstitial lung disease and elevated CEA and CA125 serum tumour markers.
Dai H; Liu J; Liang L; Ban C; Jiang J; Liu Y; Ye Q; Wang C
Respirology; 2014 Jul; 19(5):707-13. PubMed ID: 24903079
[TBL] [Abstract][Full Text] [Related]
19. Tumor markers CA 125, carcinoembryonic antigen and tumor-associated trypsin inhibitor in patients with cervical adenocarcinoma.
Leminen A
Gynecol Oncol; 1990 Dec; 39(3):358-63. PubMed ID: 2258083
[TBL] [Abstract][Full Text] [Related]
20. Clinical observations on the association between diagnosis of lung cancer and serum tumor markers in combination.
Wang WJ; Tao Z; Gu W; Sun LH
Asian Pac J Cancer Prev; 2013; 14(7):4369-71. PubMed ID: 23992005
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
